-
Kansas City Southern Gets A Downgrade Amid Increased Free Trade Risk
Wednesday, November 9, 2016 - 11:01am | 283Read More...Aegis Capital’s Jeffrey Kauffman believes that Kansas City Southern (NYSE: KSU) sahres are likely to increased risk of valuation discount of 10 percent, given the outcome of the Presidential election. Kauffman downgraded the rating on the company from Buy to Hold, while lowering the price...
-
Cytosorbents Gets Bullish Commentary On European Outlook
Wednesday, October 26, 2016 - 12:55pm | 293Read More...Aegis Capital initiated coverage of Cytosorbents Corp (NASDAQ: CTSO) with a Buy rating and $20 target price on strong outlook for European markets. The company sells Cytosorb, which removes excess inflammatory cytokines from the blood that helps preventing organ failure and death in ICU...
-
Aegis Initiates Buy On Microvision, Calls PicoP Technology 'A Leader In Fast Growing Market'
Monday, August 8, 2016 - 4:51pm | 303Read More...Aegis Capital initiated coverage on Microvision, Inc. (NASDAQ: MVIS) with a Buy rating, viewing the company's PicoP technology as a leader in the fast growing market. According to the analysts, the optical engine, capable of both miniature projection and sensing three dimensional images, have a...
-
IPO Outlook: Do 4 Biotechs Mean Maybe The IPO Market Is Back?
Tuesday, May 3, 2016 - 12:10pm | 463Read More...2016’s slow start for Initial Public Offerings (IPO) could be over, as four biotechs follow in the wake of several successful IPOs, most notably, BATS Global Markets, Inc. (BATS: BATS) and American Renal Associates Holdings Inc (NYSE: ARA). These stocks are up 25 and 26 percent, respectively...
-
Why Aegis Capital Loves Signal Genetics
Tuesday, December 29, 2015 - 3:59pm | 327Read More...In a report issued Tuesday, Aegis Capital analyst Ashok Kumar reiterated a Buy rating on shares of Signal Genetics Inc (NASDAQ: SGNL). The expert issued a $3 price target based on discounted cash flows (DCF) analysis. According to the research note, the company’s “growth strategy is...
-
Aegis Capital Reiterates Buy On CytRx As Stock Soars 17%
Tuesday, January 6, 2015 - 4:20pm | 236Read More...Aegis Capital issued an update on CytRx Corporation (NASDAQ: CYTR) Tuesday and reiterated its Buy rating and $12 price target. Analyst Yi Chen noted that the company announced “positive interim results from the ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of...
-
Aegis Capital Downgrades Recro Pharma, Says Investors Should Be Cautious
Tuesday, December 9, 2014 - 3:59pm | 207Read More...Aegis Capital downgraded Recro Pharma Inc (NASDAQ: REPH) Tuesday from Buy to Hold and did not set a price target. Analyst Yi Chen noted that “Recro Pharma started a Phase 2 clinical trial of Dex-IN, its proprietary intranasal formulation of dexmedetomidine, in late October 2014 in the...
-
UPDATE: Aegis Capital Downgrades Galectin Therapeutics
Friday, August 1, 2014 - 12:26pm | 102Read More...In a note released Friday morning, Aegis Capital analyst Raghuram Selvaraju downgraded shares of Galectin Therapeutics (NASDAQ: GALT) from Buy to Hold. The downgrade comes amid result concerns as to whether or not the company will be able to demonstrate clinical effectiveness of its lead drug...
-
UPDATE: Aegis Downgrades Ctrip.com On Limited Upside Potential
Friday, August 1, 2014 - 11:50am | 171Read More...In a note issued Friday morning, Aegis Capital downgraded CTrip.com (NASDAQ: CTRP) due to competitive risk along with declining profitability. Aegis Capital mentioned that CTrip.com is in a heavy investment phase: “Ctrip has adopted the strategy of investing heavily in product development and...
-
Aegis Capital Initiates Coverage On Auxilium Pharmaceuticals, Favors Acquisition
Thursday, June 26, 2014 - 11:34am | 159Read More...In a report released Thursday, Aegis Capital analyst Raghuram Selvaraju initiated coverage on Auxilium Pharmaceuticals (NASDAQ: AUXL) with a Buy rating and a $37.00 price target. Auxilium announced on Thursday it will acquire QLT (NASDAQ: QLT) for 3.1359 shares of Auxilium stock, equivalent to...
-
IPO Outlook for Friday, April 11: City Office, Paycom Software, Farmland Partners & More
Friday, April 11, 2014 - 7:45am | 748Read More...Ally Financial (NYSE: ALLY), Cerulean Pharma (NASDAQ: CERU), and Adamas Pharmaceuticals (NASDAQ: ADMS) opened for trading Thursday amid a stock market in free-fall. Ally Financial, formerly known as GMAC, began trading 95M shares as the US Treasury divests itself of 177M shares. The stock...
-
UPDATE: Aegis Capital Initiates Coverage On Sorrento Therapeutics On RTX-100
Wednesday, December 4, 2013 - 8:49am | 116Read More...In a report published Tuesday, Aegis Captial analyst Raghuram Selvaraju initiated a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE) and a price target of $40.00. In the report, Aegis Capital says "We are initiating coverage of Sorrento Therapeutics, Inc., with a Buy rating and an 18-month price...
-
UPDATE: Aegis Capital Initiates on Oramed Pharmaceuticals on Proprietary Drug Candidates
Wednesday, December 4, 2013 - 8:02am | 181Read More...In a report published Tuesday, Aegis Capital analyst Raghuram Selvaraju initiated a Buy rating on Oramed Pharmaceuticals (NASDAQ: ORMP) and a price target of $25.00. In the report, Aegis Capital says "We are initiating coverage of Oramed Pharmaceuticals, Inc., with a Buy rating and a 12-month...
-
Aegis Says FDA's Outlook 'Not As Negative As People Think' on Amarin
Monday, October 14, 2013 - 1:30pm | 373Read More...The outlook of Amarin shares appeared bleak following an FDA release over concerns of the Vascepa drug. On October 16, an advisory committee will convene to decide if Amarin's lead drug will help with the treatment of mixed dyslipidemia. On Monday, Aegis Capital released a statement expressing...
-
UPDATE: Aegis Capital Lowers PT on Venaxis Following Recent Dilution
Monday, August 19, 2013 - 11:26am | 136Read More...In a report published Monday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on Venaxis (NASDAQ: APPY), but lowered the price target $6.00 to $3.50. In the report, Aegis Capital noted, “We are reducing our price target on Venaxis, Inc. due to the dilution that occurred in the...
